BENGALURU (Reuters) – India’s Glenmark Pharmaceuticals Ltd said on Wednesday its version of anti-flu drug favipiravir showed promise in a late-stage study of 150 patients with mild to moderate coronavirus infection.
About 70% of patients being treated by FabiFlu achieved “clinical cure” by the fourth day of the study, compared with about 45% seen in the group treated with standard supportive care, the company said in a statement https://reut.rs/3eS12Zt.
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Saumyadeb Chakrabarty)
